Summary of Studies of 18F-FDG PET for Early Prediction of Treatment Response
| 18F-FDG PET metabolic response | |||||||||
| Reference | Year | No. of patients included in 18F-FDG PET analysis | Pathologic response criteria* | Percentage of responders | After indicated treatment cycle | Decrease in SUV | Percentage sensitivity | Percentage specificity | Percentage negative predictive value |
| Schelling et al. (8) | 2000 | 22 | pCR + pMRD | 29 | First, second | >45% after first or second | 100 (first), 83 (second) | 85 (first), 94 (second) | N/A |
| Smith et al. (9) | 2000 | 30 | pCR-macro | 38 | First | >20% | 90 | 74 | N/A |
| Rousseau et al. (10) | 2006 | 64 | >50% therapeutic effect | 56 | First, second | >40% after first or second | 61 (first), 89 (second) | 96 (first), 95 (second) | 68 (first), 85 (second) |
| Schwarz-Dose (11) | 2009 | 104 | pCR + pMRD | 16 | First, second | >45% after first, >55% after second | 73 | 63 | 90 |
| Humbert et al.† (32) | 2012 | 37 | pCR‡ | 38 | First | >75% | 64 | 83 | 79 |
| Groheux et al.† (35) | 2013 | 30 | pCR‡ | 53 | Second | >62% | 86 | 63 | N/A |
| SUV ≤ 3.0§ | 86 | 94 | 88 | ||||||
| Humbert et al.† (34) | 2014 | 54 | pCR‡ | 41 | First | >60% | 83 | 52 | 84 |
| SUV < 2.1§ | 59 | 88 | 76 | ||||||
↵* pCR = pathologic complete response, defined as absence of residual invasive tumor in breast, irrespective of lymph node status [ypT0/is ypNX], unless otherwise indicated; pMRD = minimal residual disease, defined as a few scattered foci of microscopic residual invasive tumor (≤2 mm); pCR-macro = pathologic response, defined as absence of macroscopically visible tumor.
↵‡ pCR was defined as absence of residual invasive tumor in both breast and axillary lymph nodes [ypT0/is ypN0].
↵† Results were based on HER2-positive breast cancers only.
↵§ Absolute SUVs for defining cutoff values.
N/A = not available.